Moxifloxacine Eg (Moxifloxacin)

Moxifloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes needed for DNA replication and transcription. By inhibiting these targets, the drug prevents bacterial DNA synthesis, leading to rapid bacterial cell death and a bactericidal effect against many Gram‑positive and Gram‑negative organisms.

The specific dose and duration of Moxifloxacine Eg are determined by the prescribing clinician based on the infection type, severity, patient age, renal function and other clinical factors. The prescriber will select the appropriate regimen from the product labeling.

Moxifloxacine Eg is classified as Pregnancy Category C, meaning risk cannot be ruled out. It should only be used if the potential benefit justifies the potential risk to the fetus. Limited data are available for breastfeeding; a decision should be made by the healthcare provider after weighing benefits and risks.

To order Moxifloxacine Eg, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The sales team then replies with pricing, availability, shipping details and any required import documentation.

Moxifloxacine Eg (moxifloxacin) offers a broader spectrum against Gram‑positive organisms and better activity against atypical pathogens compared with older fluoroquinolones such as ciprofloxacin. It also has a longer half‑life, allowing once‑daily dosing, but shares class‑related safety considerations like QT prolongation and tendon toxicity.

Moxifloxacine Eg should be stored at temperatures below 25 °C, in the original packaging, and protected from moisture and direct sunlight. Do not store in a bathroom or near a heat source, and keep the container tightly closed when not in use.

Moxifloxacine Eg is administered orally, usually as a tablet taken with a full glass of water. It may be taken with or without food, but antacids containing aluminum or magnesium should be spaced at least two hours apart to avoid reduced absorption.

Serious risks include tendon rupture, especially in the Achilles tendon; QT interval prolongation leading to cardiac arrhythmias; severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome; Clostridioides difficile‑associated colitis; and potential liver injury. Patients should be monitored for these events and advised to seek immediate medical attention if they occur.

Moxifloxacine Eg should be avoided in patients with a known hypersensitivity to moxifloxacin or other fluoroquinolones, those with a history of tendon disorders related to fluoroquinolone use, individuals with prolonged QT interval or uncontrolled electrolyte disturbances, and pregnant women unless the benefit outweighs the risk. Clinicians should assess each patient’s medical history before prescribing.